Sousa Hugo, Tavares Ana, Campos Carla, Marinho-Dias Joana, Brito Margarida, Medeiros Rui, Baldaque Inês, Lobo Cláudia, Leça Luís, Monteiro Paula, Tavares Fernando, Henrique Rui
Virology Service, Portuguese Oncology Institute of Porto FG EPE, Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal; Molecular Oncology & Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto FG EPE, Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal; Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus de Gualtar, 4710-057, Braga, Portugal; ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal.
Virology Service, Portuguese Oncology Institute of Porto FG EPE, Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal; Department of Pathology, Portuguese Oncology Institute of Porto (IPO-Porto), Rua Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal.
Papillomavirus Res. 2019 Dec;8:100179. doi: 10.1016/j.pvr.2019.100179. Epub 2019 Aug 1.
High-Risk Human papillomavirus (HR-HPV) full genotyping methods have been described as of great potential use in epidemiology and preventive strategies, including cervical cancer screening and HPV vaccination. We characterized the prevalence and distribution of HR-HPV genotypes in cervico-vaginal samples obtained from the Regional Cervical Cancer Screening Program from the Northern Region of Portugal. HR-HPV genotyping was performed using Anyplex™ II HPV-HR Detection kit in 105,458 women enrolled between August 2016 and December 2017. HR-HPVs were detected in 10,665 women (10.2%) with a prevalence ranging from 6.2 to 17.1% depending on age, and from 8.7 to 10.7% depending on geographical location. Multiple infections with two or more HR-HPVs were detected in 2736 (25.7%) of HR-HPV women ranging from 16.5 to 31.0% depending on age. Amongst HR-HPV positive women, HPV-16 (17.5%), HPV-39 (16.7%), HPV-31 (15.0%), HPV-68 (13.2%), HPV-52 (10.7%) and HPV-51 (10.6%) were the most common genotypes in our population, being HPV-16 more frequent in women aged from 30 to 45 years and HPV-39 in 50-65 years. Results also show that HPV16/18 are present in 22.1% and HPV16/18/31/33/45/52/58 in 47.6% of HR-HPV positive women. This is the largest study on HR-HPV genotyping for Cervical Cancer Screening in European populations and provides critical data for program management and vaccine policy.
高危型人乳头瘤病毒（HR-HPV）全基因分型方法在流行病学及预防策略中具有巨大潜在应用价值，包括宫颈癌筛查和HPV疫苗接种。我们对从葡萄牙北部地区宫颈癌筛查项目中获取的宫颈阴道样本中的HR-HPV基因型的流行情况及分布特征进行了研究。在2016年8月至2017年12月期间纳入的105458名女性中，使用Anyplex™ II HPV-HR检测试剂盒进行HR-HPV基因分型。共检测出10665名女性（10.2%）感染HR-HPV，患病率因年龄而异，范围在6.2%至17.1%之间，因地理位置而异，范围在8.7%至10.7%之间。在2736名（25.7%）感染HR-HPV的女性中检测到两种或更多种HR-HPV的多重感染，其比例因年龄而异，范围在16.5%至31.0%之间。在HR-HPV阳性女性中，HPV-16（17.5%）、HPV-39（16.7%）、HPV-31（15.0%）、HPV-68（13.2%）、HPV-52（10.7%）和HPV-51（10.6%）是最常见的基因型，其中HPV-16在30至45岁女性中更为常见，HPV-39在50至65岁女性中更为常见。结果还显示，22.1%的HR-HPV阳性女性感染了HPV16/18，47.6%的HR-HPV阳性女性感染了HPV16/18/31/33/45/52/58。这是欧洲人群中关于宫颈癌筛查的HR-HPV基因分型的最大规模研究，为项目管理和疫苗政策提供了关键数据。
